Skip to main content

Now I Trust My Heart to Lipitor OTC


The New York Times just published an excellent piece by Paula Span on a plan by Pfizer to make its cholesterol blockbuster drug Lipitor an over-the-counter (OTC) medication. A couple things caught my eye when reading this piece, not the least of which was the story was picked up by the Times after this tweet by our very own Ken Covinsky (FYI, in the twitterverse, Ken goes the name @geri_doc):
Pfizer wants to make Lipitor OTC. Just happens to be coming off patent. Message to FDA: no No NO NO! NO!! NO!!!

Well it looks like Ken’s excellent use of exclamation marks worked, as it did get attention. But what’s the big deal? It’s just Lipitor.

As Paula Span reports in the Times, a statin going over the counter is a big deal, both from a financial perspective for Pfizer, and from a patient safety perspective. Lipitor’s patent protection expires this November when at least one generic comes to the US market, so Pfizer is desperately looking for a way to continue milking this cash cow. One of their current ad campaigns shows just how nervous they are about patients switching to generics:
“If you're taking Lipitor for high cholesterol and it's working, why switch?”

Claritin is a great example of a drug company desire to fight for room in the over the counter shelf once patent protection was lost. Claritin was bringing in $3 billion prior to losing US patent protection in 2002. Schering-Plough protected some of those sales by launching an over-the-counter version of Claritin.  Last year, that over-the-counter version had $400 million in sales. Not as good as pre-patent protection, but still a nice chunk of change.

So, if Lipitor over-the-counter is a win for Pfizer, is it also a win for patients? Paula Span’s article does a much better job than I could ever do in clarifying both the pros and cons of making a drug like Lipitor over-the-counter, and I encourage you to read it and comment at the New Old Age website.

However, you may also just decide that the world has gone mad at even the notion of making something like Lipitor over the counter.  If that's the case, have no fear.  Both Seroquel and Zyprexa are coming off patent protection in 2012.

by: Eric Widera

Comments

Amy Corcoran said…
While I would love to see a statin over the counter in hopes that it would be less expensive to our older patients, I have concerns about all of the side effects. In the geripal world I am often dose reducing or discontinuing statins in those with life-limiting illness (which is still controversial). For example, a hospice patient with end-stage COPD or CHF may not have coverage for their statin medication - who should pay for it? Should the patient even be on the medication?
Sathish Kumar said…
I've been taking Lipitor pills for over 4 years-no side effects noted and my cholesterol is now 132, Trigycedrides 84, LDL 65, and HDL 50.

Popular posts from this blog

Dying without Dialysis

There is a terrific article in this weeks Journal of Pain and Symptom Management by Fliss Murtagh of King's College in London about the epidemiology of symptoms for patients with advanced renal failure who die without dialysis.  This study is important because while we know that patients with advanced renal failure have a limited life expectancy and the average age of initiation of hemodialysis is increasing, we know little about the alternatives to hemodialysis.  Specifically, we know nothing about symptoms affecting quality of life among patients who elect not to start dialysis (so called "conservative management" - is this the best label?).  This article provides a terrific counterpoint to the article in last years NEJM showing that nursing home residents who initiated hemodialysis tended to die and decline in function (see GeriPal write up here). 

The study authors followed patients with the most advanced form of chronic kidney disease (the new name for renal failu…

Language Matters: Podcast with Brian Block and Anna DeForest

One of our first GeriPal posts was titled "Rant on Terminology," by Patrice Villars, NP.  In the spirit of looking back over our first 10 years, here is the opening paragraph to that post:

News Headlines read: Sen. Edward Kennedy loses battle with cancer. Really, he lost? I thought he died from a malignant brain tumor, an “aggressive” brain tumor. The median survival is less than a year for people for his particular tumor. Kennedy was diagnosed in May of 2008. He lived over 15 months after diagnosis. What a loser. He must not have fought hard enough. Huh? I thought he spent most of his life battling for social and health care reform in America. In this week's GeriPal podcast we take a deeper dive into this issue of language and medicine.  We are joined by guests Anna DeForest, MD, MFA, a resident in Neurology at Yale, and Brian Block, MD, a pulmonary critical care fellow at UCSF.  

Anna recently published a paper in the NEJM describing her reaction to hearing terms like, &…

The Dangers of Fleet Enemas

The dangers of oral sodium phosphate preparations are fairly well known in the medical community. In 2006 the FDA issued it’s first warning that patients taking oral sodium phosphate preparations are at risk for potential for acute kidney injury. Two years later, over-the-counter preparations of these drugs were voluntarily withdrawn by the manufacturers.  Those agents still available by prescription were given black box warnings mainly due to acute phosphate nephropathy that can result in renal failure, especially in older adults. Despite all this talk of oral preparations, little was mentioned about a sodium phosphate preparation that is still available over-the-counter – the Fleet enema.

Why Oral Sodium Phosphate Preparations Are Dangerous 

Before we go into the risks of Fleet enemas, lets spend just a couple sentences on why oral sodium phosphate preparations carry significant risks. First, oral sodium phosphate preparations can cause significant fluid shifts within the colon …